Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
Ludwig Kappos(Novartis (Switzerland)), Rupert Sandbrink(Io Therapeutics (United States)), Hans‐Peter Hartung(The University of Sydney), Frederik Barkhof(Netherlands Institute for Neuroscience), Vivian Lanius(Bayer (Germany)), Gilles Edan(Centre National de la Recherche Scientifique), S. Dahms(Bayer (Germany)), David H. Miller(National Hospital for Neurology and Neurosurgery), Ernst‐Wilhelm Radü(University Hospital of Basel), Mark S. Freedman, Chris H. Polman(Vrije Universiteit Amsterdam), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Lars Bauer(UCB Pharma (Germany)), Christoph Pohl
Cited by 502
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k